Eikon Therapeutics, Inc. (EIKN) Net Income — Quarterly & Annual

Screener

Net Income at other companies

Gilead SciencesGILD

-$10.5B-636%

IDEAYA Biosciences, Inc.IDYA

-$98.54M-36.5%

Inhibrx Biosciences, Inc.INBX

-$33.44M+22.8%

OnKure Therapeutics, Inc.OKUR

-$15.16M+4.8%

ImmunomeIMNM

-$53.84M-29.3%

Erasca, Inc.ERAS

-$183.44M-492%

Other financials

Income statement

Operating income-$87.3M-22.3%

Net income-$83.0M-21.6%

EPS (diluted)-$2.46+90.9%

Balance sheet

Cash & equivalents$161.2M-21.2%

Total debt$254.8M—

Total equity$550.7M+186%

Total assets$850.8M—

Cash flow

Operating cash flow-$89.8M-64.7%

CapEx$262.0K-98.8%

Free cash flow-$90.1M-17.1%

Valuation

Market cap$498.62M-36.3%

Enterprise value$592.29M—

Returns & leverage

Debt / equity0.5×—

Current ratio11.8×—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026. Open the filing →

Filed: May 11, 2026, 4:13 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001193125-26-216791

FAQ

What is Eikon Therapeutics, Inc.'s net income?: Eikon Therapeutics, Inc. (EIKN) reported net income of -$82.96M in Q1 2026.
What does net income mean?: Net income as the starting point for the indirect method operating cash flow reconciliation.

Ask your AI about Eikon Therapeutics, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk